213 related articles for article (PubMed ID: 24296664)
21. Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.
DeVay RM; Yamamoto L; Shelton DL; Liang H
PLoS One; 2015; 10(4):e0125127. PubMed ID: 25905719
[TBL] [Abstract][Full Text] [Related]
22. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
[TBL] [Abstract][Full Text] [Related]
23. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.
Qian YW; Schmidt RJ; Zhang Y; Chu S; Lin A; Wang H; Wang X; Beyer TP; Bensch WR; Li W; Ehsani ME; Lu D; Konrad RJ; Eacho PI; Moller DE; Karathanasis SK; Cao G
J Lipid Res; 2007 Jul; 48(7):1488-98. PubMed ID: 17449864
[TBL] [Abstract][Full Text] [Related]
24. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor.
Duff CJ; Scott MJ; Kirby IT; Hutchinson SE; Martin SL; Hooper NM
Biochem J; 2009 May; 419(3):577-84. PubMed ID: 19196236
[TBL] [Abstract][Full Text] [Related]
25. Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation.
Benjannet S; Hamelin J; Chrétien M; Seidah NG
J Biol Chem; 2012 Sep; 287(40):33745-55. PubMed ID: 22875854
[TBL] [Abstract][Full Text] [Related]
26. Plasma PCSK9 preferentially reduces liver LDL receptors in mice.
Grefhorst A; McNutt MC; Lagace TA; Horton JD
J Lipid Res; 2008 Jun; 49(6):1303-11. PubMed ID: 18354138
[TBL] [Abstract][Full Text] [Related]
27. The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.
Saavedra YG; Day R; Seidah NG
J Biol Chem; 2012 Dec; 287(52):43492-501. PubMed ID: 23105118
[TBL] [Abstract][Full Text] [Related]
28. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
[TBL] [Abstract][Full Text] [Related]
29. Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels.
Fruchart Gaillard C; Ouadda ABD; Ciccone L; Girard E; Mikaeeli S; Evagelidis A; Le Dévéhat M; Susan-Resiga D; Lajeunesse EC; Nozach H; Ramos OHP; Thureau A; Legrand P; Prat A; Dive V; Seidah NG
Mol Metab; 2023 Jan; 67():101662. PubMed ID: 36566984
[TBL] [Abstract][Full Text] [Related]
30. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
Lipari MT; Li W; Moran P; Kong-Beltran M; Sai T; Lai J; Lin SJ; Kolumam G; Zavala-Solorio J; Izrael-Tomasevic A; Arnott D; Wang J; Peterson AS; Kirchhofer D
J Biol Chem; 2012 Dec; 287(52):43482-91. PubMed ID: 23135270
[TBL] [Abstract][Full Text] [Related]
31. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route.
Poirier S; Mayer G; Poupon V; McPherson PS; Desjardins R; Ly K; Asselin MC; Day R; Duclos FJ; Witmer M; Parker R; Prat A; Seidah NG
J Biol Chem; 2009 Oct; 284(42):28856-64. PubMed ID: 19635789
[TBL] [Abstract][Full Text] [Related]
32. Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain.
Strøm TB; Holla ØL; Tveten K; Cameron J; Berge KE; Leren TP
Mol Genet Metab; 2010 Sep; 101(1):76-80. PubMed ID: 20659812
[TBL] [Abstract][Full Text] [Related]
33. c-IAP1 binds and processes PCSK9 protein: linking the c-IAP1 in a TNF-α pathway to PCSK9-mediated LDLR degradation pathway.
Xu W; Liu L; Hornby D
Molecules; 2012 Oct; 17(10):12086-101. PubMed ID: 23085658
[TBL] [Abstract][Full Text] [Related]
34. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.
Cameron J; Holla ØL; Ranheim T; Kulseth MA; Berge KE; Leren TP
Hum Mol Genet; 2006 May; 15(9):1551-8. PubMed ID: 16571601
[TBL] [Abstract][Full Text] [Related]
35. PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study.
Valenti V; Noto D; Giammanco A; Fayer F; Spina R; Altieri GI; Ingrassia V; Scrimali C; Barbagallo CM; Brucato F; Misiano G; Cefalù AB; Averna MR
Atherosclerosis; 2020 Jan; 292():209-214. PubMed ID: 31564372
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
[TBL] [Abstract][Full Text] [Related]
37. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.
Kosenko T; Golder M; Leblond G; Weng W; Lagace TA
J Biol Chem; 2013 Mar; 288(12):8279-8288. PubMed ID: 23400816
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
Maxwell KN; Fisher EA; Breslow JL
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2069-74. PubMed ID: 15677715
[TBL] [Abstract][Full Text] [Related]
39. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.
Butkinaree C; Canuel M; Essalmani R; Poirier S; Benjannet S; Asselin MC; Roubtsova A; Hamelin J; Marcinkiewicz J; Chamberland A; Guillemot J; Mayer G; Sisodia SS; Jacob Y; Prat A; Seidah NG
J Biol Chem; 2015 Jul; 290(30):18609-20. PubMed ID: 26085104
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding.
Gu HM; Adijiang A; Mah M; Zhang DW
J Lipid Res; 2013 Dec; 54(12):3345-57. PubMed ID: 24103783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
